Aron D. Thall

4.2k total citations · 1 hit paper
56 papers, 3.4k citations indexed

About

Aron D. Thall is a scholar working on Surgery, Immunology and Oncology. According to data from OpenAlex, Aron D. Thall has authored 56 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Surgery, 17 papers in Immunology and 16 papers in Oncology. Recurrent topics in Aron D. Thall's work include Xenotransplantation and immune response (24 papers), Lymphoma Diagnosis and Treatment (10 papers) and T-cell and B-cell Immunology (9 papers). Aron D. Thall is often cited by papers focused on Xenotransplantation and immune response (24 papers), Lymphoma Diagnosis and Treatment (10 papers) and T-cell and B-cell Immunology (9 papers). Aron D. Thall collaborates with scholars based in United States, Italy and France. Aron D. Thall's co-authors include John B. Lowe, Petr Malý, Uri Galili, Megan Sykes, Kevin M. Gersten, Guiying Cheng, Ole Hindsgaul, Rory M. Marks, Clare Rogers and Robert J. Kelly and has published in prestigious journals such as Cell, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Aron D. Thall

56 papers receiving 3.3k citations

Hit Papers

The α(1,3)Fucosyltransferase Fuc-TVII Controls Leukocyte ... 1996 2026 2006 2016 1996 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The α(1,3)Fucosyltransferase Fuc-TVII Controls Leukocyte Trafficking through an Essential Role in L-, E-, and P-selectin Ligand Biosynthesis
    1996 615 citations Petr Malý, Aron D. Thall et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aron D. Thall United States 27 1.4k 1.3k 900 819 716 56 3.4k
Laura S. Grosmaire United States 24 3.9k 2.9× 240 0.2× 807 0.9× 924 1.1× 405 0.6× 39 4.9k
Eileen A. Elliott United States 22 1.6k 1.2× 317 0.2× 741 0.8× 374 0.5× 257 0.4× 24 2.8k
Mark W. Appleby United States 17 2.9k 2.1× 188 0.1× 849 0.9× 661 0.8× 548 0.8× 24 3.8k
Miriam A. Shelef United States 23 2.3k 1.7× 211 0.2× 1.2k 1.3× 432 0.5× 247 0.3× 44 3.8k
Tomoya Katakai Japan 28 2.1k 1.6× 236 0.2× 881 1.0× 571 0.7× 237 0.3× 63 3.1k
Roland J. Levinsky United Kingdom 20 1.9k 1.4× 283 0.2× 1.1k 1.3× 386 0.5× 1.1k 1.5× 41 3.5k
Wasif N. Khan United States 32 2.6k 1.9× 182 0.1× 1.0k 1.1× 540 0.7× 344 0.5× 69 3.9k
Jeanette Dilley United States 24 930 0.7× 189 0.1× 978 1.1× 599 0.7× 699 1.0× 32 2.5k
Gregory E. Plautz United States 29 1.6k 1.2× 383 0.3× 2.4k 2.6× 1.2k 1.5× 1.6k 2.2× 56 4.2k
Myriam Armant United States 28 1.1k 0.8× 258 0.2× 720 0.8× 376 0.5× 215 0.3× 55 2.2k

Countries citing papers authored by Aron D. Thall

Since Specialization
Citations

This map shows the geographic impact of Aron D. Thall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aron D. Thall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aron D. Thall more than expected).

Fields of papers citing papers by Aron D. Thall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aron D. Thall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aron D. Thall. The network helps show where Aron D. Thall may publish in the future.

Co-authorship network of co-authors of Aron D. Thall

This figure shows the co-authorship network connecting the top 25 collaborators of Aron D. Thall. A scholar is included among the top collaborators of Aron D. Thall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aron D. Thall. Aron D. Thall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gopal, Ajay K., Ronald Levy, Roch Houot, et al.. (2020). First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clinical Cancer Research. 26(11). 2524–2534. 45 indexed citations
2.
Cohen, Ezra E.W., Michael J. Pishvaian, Dale R. Shepard, et al.. (2019). A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 7(1). 342–342. 45 indexed citations
3.
Segal, Neil H., Aiwu Ruth He, Toshihiko Doi, et al.. (2018). Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Clinical Cancer Research. 24(8). 1816–1823. 181 indexed citations
4.
Tolcher, Anthony W., Mario Sznol, Siwen Hu‐Lieskovan, et al.. (2017). Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 23(18). 5349–5357. 183 indexed citations
5.
Blais, Normand, D. Ross Camidge, Derek J. Jonker, et al.. (2013). Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study. Investigational New Drugs. 31(6). 1487–1498. 3 indexed citations
6.
Novello, Silvia, Carlos Camps, Francesco Grossi, et al.. (2011). Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases. Journal of Thoracic Oncology. 6(7). 1260–1266. 41 indexed citations
7.
Chow, Laura Q.M., Normand Blais, Derek J. Jonker, et al.. (2011). A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 69(3). 709–722. 11 indexed citations
8.
Reck, Martin, Norbert Frickhofen, S. Cedrés, et al.. (2010). Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. Lung Cancer. 70(2). 180–187. 38 indexed citations
9.
10.
Abe, Masahiro, Jane Cheng, Qi Jin, et al.. (2002). Elimination of Porcine Hemopoietic Cells by Macrophages in Mice. The Journal of Immunology. 168(2). 621–628. 54 indexed citations
11.
Pels, Hendrik, et al.. (2002). Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab. Journal of Neuro-Oncology. 59(3). 213–216. 54 indexed citations
12.
Bühler, Léo H., Kenneth M. Yamada, Hiroshi Kitamura, et al.. (2001). Miniature swine and hDAF pig kidney transplantation in baboons treated with a nonmyeloablative regimen and CD154 blockade. Transplantation Proceedings. 33(1-2). 716–716. 11 indexed citations
13.
14.
Ohdan, Hideki, Kirsten G. Swenson, Yong‐Guang Yang, et al.. (2000). Mac-1-Negative B-1b Phenotype of Natural Antibody-Producing Cells, Including Those Responding to Galα1,3Gal Epitopes in α1,3-Galactosyltransferase-Deficient Mice. The Journal of Immunology. 165(10). 5518–5529. 107 indexed citations
15.
Bühler, Léo H., Michel Awwad, M. Basker, et al.. (2000). A nonmyeloablative regimen with CD40L blockade leads to humoral and cellular hyporesponsiveness to pig hematopoietic cells in baboons. Transplantation Proceedings. 32(5). 1100–1100. 5 indexed citations
16.
Huang, Min‐Chuan, Thomas Moll, Petr Malý, et al.. (2000). P-selectin Glycoprotein Ligand-1 and E-selectin Ligand-1 Are Differentially Modified by Fucosyltransferases Fuc-TIV and Fuc-TVII in Mouse Neutrophils. Journal of Biological Chemistry. 275(40). 31353–31360. 52 indexed citations
17.
McKenzie, Ian F. C., et al.. (1998). A MURINE MODEL OF ANTIBODY-MEDIATED HYPERACUTE REJECTION BY GALACTOSE-??(1,3)GALACTOSE ANTIBODIES IN Gal o/o MICE1. Transplantation. 66(6). 754–763. 50 indexed citations
18.
Thall, Aron D., et al.. (1991). The α-galactosyl epitope on mammalian thyroid cells. European Journal of Endocrinology. 124(6). 692–699. 33 indexed citations
19.
Galili, Uri, Aron D. Thall, & Bruce A. Macher. (1990). Evolution of the Galα1-3Galβ1-4GlcNAc-R Epitope in Mammals. Trends in Glycoscience and Glycotechnology. 2(7). 303–318. 6 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura S. Grosmaire Breakdown of academic impact, for papers by Eileen A. Elliott Breakdown of academic impact, for papers by Mark W. Appleby Breakdown of academic impact, for papers by Miriam A. Shelef Breakdown of academic impact, for papers by Tomoya Katakai Breakdown of academic impact, for papers by Roland J. Levinsky Breakdown of academic impact, for papers by Wasif N. Khan Breakdown of academic impact, for papers by Jeanette Dilley Breakdown of academic impact, for papers by Gregory E. Plautz Breakdown of academic impact, for papers by Myriam Armant
Rankless by CCL
2026